Rockville, MD (PRWEB) January 11, 2013
Blue Door Pharmacies, LLC (T/A Blue Door Pharma) announces it has executed a five year, exclusive joint partnership with Global Energy Markets, LLC for the sale and global distribution of pharmaceuticals and a low cost tetravalent meningitis vaccine. Operating under the joint partnership name BlueGem Global, the companies are in negotiations with organizations in Algeria, the Dominican Republic, Ghana, Indonesia and Iran.
“Global Energy Markets needed Blue Door Pharma’s expertise, and they needed ours,” said Global Energy Markets President and CEO, Sina Soumekhian, “For years our clients have asked for pharmaceutical access, and with this partnership we can provide it. Plus, we believe the low cost meningitis vaccine we provide will prove to be highly desirable in our target markets.”
Global Energy Markets has a broad network of international contacts and a license issued by the U.S. Department of Treasury, Office of Foreign Assets Control (OFAC), allowing them to export items to countries under US sanction. “It is a strong marriage of skills, expertise and regulatory licensing on both sides of the equation,” said Dr. Sheila Alizadeh, Founder and CEO of Blue Door Pharma.
Read the full story at http://www.prweb.com/releases/2013/1/prweb10310124.htm.
'/>"/>
| Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved |
Related medicine news :
1. FDA, States Weigh Pharmacy Regulation in Wake of Meningitis Outbreak
2. ShopPharmacyCounter.com Unveils PhenObestin 37.5 to Offset Obesity Effectively
3. Pharmacy researcher finds most popular weight-loss drug strongly alters other drug therapies
4. Devalued and distrusted: Can the pharmaceutical industry restore its broken image?
5. Women’s Excellence in Bladder Control Partners with University Compounding Pharmacy in Troy, MI to Help Women with Chronic Pelvic Pain Conditions
6. Report finds Big Pharma is doing more for access to medicine in developing countries
7. Treating cocaine dependence: A promising new pharmacotherapy
8. UBC professor wins Canadas top pharmaceutical research award
9. Compounding Pharmacists Oppose Greater U.S. Oversight
10. Owner of Meningitis-Linked Pharmacy Declines to Testify Before Congress
11. Edison Pharmaceuticals announces initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |